COLL
Collegium Pharmaceutical Inc
22.50$
-1.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -83.6% | +238.1% | +10.2% | +20.0% | +121.2% | -25.4% | +60.7% | |
| – | -8.6% | +283.0% | -9.3% | +18,571.4% | -86.0% | +297.5% | +12.0% | +101.6% | +7.4% | +13.3% | +30.5% | |
| – | +9,940.9% | +162.0% | +37.3% | +73.4% | +20.0% | +32.6% | +10.7% | -5.7% | +18.6% | +19.4% | +29.3% | |
| – | +108,950.0% | +163.8% | +69.6% | +238.9% | -50.0% | +32.6% | -345.5% | – | – | – | – | |
| – | – | +281.1% | -119.7% | – | -62.7% | -205.0% | – | -194.3% | – | -353.0% | – | |
| – | +4,425.0% | +722.4% | -66.7% | +2,360.0% | -73.6% | +5,705.7% | -99.5% | -16.6% | -71.6% | +258.4% | +5.3% | |
| – | +4,425.0% | +722.4% | -66.7% | +2,360.0% | -73.6% | +5,705.7% | -99.5% | +29,410.9% | -87.7% | +306.4% | -77.9% | |
| – | – | +0.0% | -97.0% | – | – | – | +73.2% | – | – | – | – | |
| – | +96,977.8% | -64.8% | -95.4% | -149.1% | +46.8% | +174.3% | +2,022.4% | -70.6% | +433.3% | -20.0% | -58.2% | |
| – | -111.2% | +98.3% | +0.0% | – | +2,708.0% | +0.0% | -117.8% | +50.0% | -12.1% | – | -1,036.1% | |
| – | +863.5% | +16.9% | -75.3% | -450.1% | – | +13,936.0% | -131.2% | – | -132.1% | -56.8% | +81.9% | |
| – | – | -38.8% | -160.0% | – | -16.0% | -71.6% | +85.3% | -203.5% | – | -324.9% | – | |
| – | – | – | – | – | -85.3% | -1,411.0% | – | +20.7% | +123.7% | -25.9% | +61.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.